4th International AIDS Society Conference on HIV Pathogenesis and Treatment Sydney, Australia - July 22 - 25, 2007

RANDOMISED COMPARATIVE STUDY OF PATIENTS TOLERANCE OF AND ADHERENCE TO COMBIVIR AND TENOFOVIR VERSUS STAVUDINE LAMIVUDINE AND TENOFOVIR AS HIV POST- EXPOSURE PROPHYLAXIS(PEP)

IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOPDC02

Hawkins D., Higgs C., Mandalia S., Nwokolo N.
Chelsea and Westminster Hospital, Sexual Health and HIV, London, United Kingdom

OBJECTIVES: Adherence to PEP regimens is considered highly important to their efficacy. Previous studies have not been randomised but have suggested that AZT and some PI (indinavir and nelfinavir) containing regimens are poorly tolerated. The aim of this randomised study was to compare the tolerability safety and adherence of 2 different thymidine analogue tenofovir based triple nucleoside/nucleotide combinations as HIV PEP.

METHODS: We undertook an open label study of Combivir/tenofovir versus stavudine/lamivudine/tenofovir in patients being considered for HIV PEP. Enrolled subjects were asked to complete an Impact of Symptoms Scale and a validated adherence questionnaire on completing therapy which were analysed with non parametric and parametric tests respectively.

RESULTS: A total of 74 patients were randomised 39 receiving an AZT containing combination and 35 receiving the alternate thymidine analogue d4t in combination.There have been no HIV transmissions to date. 14 patients prematurely discontinued treatment 6/39 in the AZT group and 8/35 in the d4t group.One in each arm switched their PEP to the alternate study arm. Adherence was otherwise good in both arms. However a higher prevalence of anxiety was observed in the AZT arm 69.6% and there was some evidence to suggest greater numbers of subjects experienced anxiety in this arm 14/39 (36%) compared to the d4t arm 6/35 (17%) p=0.069. Although a greater prevalence of nausea was observed in the AZT arm this was NS p=0.25 (59% v 43%). Moreover the AZT arm showed greater severity and recorded 90% (9/10) of the vomiting events p=0.03.

CONCLUSIONS: Our study has the benefit of being randomised and confirms that replacing AZT by d4t in a tenofovir based regimen leads to better tolerance. In view of its significant short term poor tolerability even with routinely prescribed antiemetics it might be wise to eschew the use of AZT in PEP regimens. Suitable combinations might be TDF/FTC or TDF/3TC along with d4t or better tolerated PIs.

Download PDF of this abstract.

Download Power Point Presentation.

2007-07-22
MOPDC02
The Treatment-Prevention Nexus

Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.